Indicated for: type 2 diabetes mellitus
Substance: vildagliptin + metformin (DPP-4 inhibitor + biguanide antidiabetic)
ATC: A10BD08 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs)
The combination of vildagliptin and metformin is used for the treatment of type 2 diabetes, particularly in patients whose glycemic control is inadequate with metformin or other antidiabetic medications alone. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, thereby enhancing insulin secretion and reducing glucagon production. Metformin, on the other hand, reduces hepatic glucose production and improves insulin sensitivity.
This combination is administered orally, usually twice daily, depending on the physician's recommendations and the patient's blood glucose levels. It is important for patients to follow a balanced diet and engage in regular physical activity to maximize the benefits of the treatment.
Common side effects include nausea, diarrhea, abdominal pain, and, in rare cases, hypoglycemia. Additionally, metformin may increase the risk of lactic acidosis, a rare but serious complication.
The combination of vildagliptin and metformin provides an effective option for managing type 2 diabetes, helping to improve glycemic control and reduce the risk of complications associated with this chronic condition.